What is Sermorelin?
Sermorelin is a growth-hormone-releasing-hormone fragment with a historical pediatric medicine record. That history needs to be distinguished from current wellness marketing.
Biological role or research focus
Growth hormone-releasing hormone fragment.
A historical Geref regulatory determination does not establish the approval status of a current seller formulation.
Names you may encounter
sermorelin acetate · Geref
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- GHRH(1–29) peptide
- Main research area
- Pituitary growth-hormone signaling
- Evidence featured
- Human open-label study
- Source check
- October 4, 2026
Quick answers
- Is Sermorelin FDA approved?
- It was approved but is no longer marketed. Geref (NDA 019863 and NDA 020443, approved 1990/1997) for growth hormone deficiency testing/treatment in children; both are listed in Drugs@FDA as discontinued. Source ↗
- Is Sermorelin safe?
- Sermorelin (Geref) was FDA-approved for children with growth hormone deficiency but is no longer marketed; older pediatric studies reported flushing and injection pain most often. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Sermorelin banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.4 Growth hormone releasing factors). Source ↗
- Has the FDA taken action over Sermorelin?
- Yes. Our records list 1 FDA action naming it, most recently on December 10, 2024: FDA warning letter to a "research peptide" seller (Xcel Research) naming "SERMORELIN", retatrutide, cagrilintide and others as unapproved new drugs despite research-use-only labeling. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Geref pediatric growth study (1996) | Human open-label study | 110 previously untreated children with growth-hormone deficiency; 86 eligible for efficacy analysis. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human open-label study · 1996
Geref pediatric growth study
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.
- Population / model
- 110 previously untreated children with growth-hormone deficiency; 86 eligible for efficacy analysis.
- Study design
- Multicenter treatment for up to one year, measuring height velocity and safety.
- Main finding
- Average height velocity increased from 4.1 cm/year at baseline to 7.2 cm/year at 12 months.
- Limits & context
- There was no blinded placebo comparison. Growth in hormone-deficient children cannot establish anti-aging, body-composition, or performance benefits in adults.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming Sermorelin as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. ↗
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 Jan 1 · Journal Article, Review
Read available full text ↗
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. ↗
Sports medicine (Auckland, N.Z.) · 2026 Aug · Journal Article, Review
Advances in the detection of growth hormone releasing hormone synthetic analogs. ↗
Drug testing and analysis · 2021 Nov · Journal Article, Validation Study
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. ↗
The Journal of sports medicine and physical fitness · 2026 Jul · Journal Article, Review
Risks & interactions
Sermorelin (Geref) was FDA-approved for children with growth hormone deficiency but is no longer marketed; older pediatric studies reported flushing and injection pain most often.
Geref's label is not available on Drugs@FDA; FDA found in 2013 that it was not withdrawn for safety or effectiveness reasons. Data come mainly from 1990s pediatric studies; adult, long-term and anti-aging safety is not established.
No condition tags: its FDA label does not single out these conditions. If a condition applies to you, talk to a doctor or pharmacist first.
Common side effects
- facial flushing
- injection-site pain
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Federal Register 2013: Geref not withdrawn for safety or effectiveness reasons ↗ · Drugs@FDA: Geref, NDA 020443 ↗ · Prakash and Goa, BioDrugs 1999: sermorelin review in children with GH deficiency ↗ · Thorner et al., J Clin Endocrinol Metab 1996: Geref International Study Group ↗
Safety evidence & remaining uncertainty
The pediatric growth study provides limited safety observations in that setting. It cannot establish adult anti-aging safety, particularly with different formulations or other hormone-active treatments.
Source: FDA · Geref determination (2013) ↗
Regulatory status
- U.S. FDA approval
- Approved, now discontinued
Geref (NDA 019863 and NDA 020443, approved 1990/1997) for growth hormone deficiency testing/treatment in children; both are listed in Drugs@FDA as discontinued. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.4 Growth hormone releasing factors
Named explicitly ("sermorelin"). source
FDA actions
- FDA warning letter to a "research peptide" seller (Xcel Research) naming "SERMORELIN", retatrutide, cagrilintide and others as unapproved new drugs despite research-use-only labeling. (2024-12-10) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
A 2013 FDA determination stated that discontinued Geref products were not withdrawn for safety or effectiveness reasons. It does not confer approval on a current compounded or research seller’s preparation.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
It stimulates release of growth hormone through the pituitary pathway. Response depends on the underlying endocrine system and is not equivalent to administering growth hormone itself.
Molecular structure
Questions worth asking
- Is the speaker citing a historical product or a current formulation?
- What current source supports the exact product claim?
- A historical Geref regulatory determination does not establish the approval status of a current seller formulation.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does historical Geref approval validate every sermorelin product today?
No. Regulatory status belongs to the specific product.
Does childhood height improvement prove adult muscle or longevity benefits?
No. Different populations and outcomes require their own evidence.
References & editorial record
- FDA · Geref determination (2013) ↗
- Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
